When the possibilities for disease prevention are endless, challenges are close behind

Article

We're learning that the possibilities for prevention of disease through vaccines are farther-reaching than we imagined during the last century.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Related Content
FDA notifies providers of safety-related changes to prescribing information of maralixibat, odevixibat | Image Credit: Contemporary Pediatrics

FDA notifies providers of safety-related changes to prescribing information of maralixibat, odevixibat

Joshua Fitch, Senior Editor
June 30th 2025
Article

The updated labeling includes a new contraindication for patients with prior or active hepatic events.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
New 2022 data: Pediatric mental health hospitalizations decline overall, increase for females | Image Credit: © Lumos sp - © Lumos sp - stock.adobe.com.

New 2022 data: Pediatric mental health hospitalizations decline overall, increase for females

Joshua Fitch, Senior Editor
June 30th 2025
Article

The total number of pediatric mental health hospitalizations declined in 2022, the first time observed since 2009.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Mercedes E. Gonzalez, MD
June 27th 2025
Article

Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors | Image Credit: © lexiconimages - © lexiconimages - stock.adobe.com.

Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors

Joshua Fitch, Senior Editor
June 26th 2025
Article

New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.

© 2025 MJH Life Sciences

All rights reserved.